Sigma-1 receptor agonist properties that mediate the fast-onset antidepressant effect of hypidone hydrochloride (YL-0919)

  • Eur J Pharmacol. 2023 Mar 8;175647. doi: 10.1016/j.ejphar.2023.175647.
Peng Ren  1 Jing-Ya Wang  1 Hong-Lei Chen  2 Hai-Xia Chang  1 Zhi-Rui Zeng  3 Guang-Xiang Li  1 Hui Ma  1 Yong-Qi Zhao  4 Yun-Feng Li  5
Affiliations
  • 1. Beijing Institute of Basic Medical Sciences, Beijing, China.
  • 2. Graduate Collaborative Training Base of Academy of Military Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.
  • 3. Guizhou Provincial Key Laboratory of Pathogenesis & Drug Research on Common Chronic Diseases, Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China.
  • 4. Beijing Institute of Basic Medical Sciences, Beijing, China. Electronic address: [email protected].
  • 5. Beijing Institute of Basic Medical Sciences, Beijing, China; Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing, China. Electronic address: [email protected].
Abstract

The most intriguing characteristic of the sigma-1 receptor is its ability to regulate multiple functional proteins directly via protein-protein interactions, giving the sigma-1 receptor the powerful ability to regulate several survival and metabolic functions in cells, fine tune neuronal excitability, and regulate the transmission of information within brain circuits. This characteristic makes sigma-1 receptors attractive candidates for the development of new drugs. Hypidone hydrochloride (YL-0919), a novel structured antidepressant candidate developed in our laboratory, was found to possess selective sigma-1 receptor agonist profiles via molecular docking, radioligand receptor binding assays, and receptor functional experiments. In vivo studies have revealed that YL-0919 elicits a fast-onset antidepressant activity (within one week) that can be attenuated with pretreatment of the selective sigma-1 receptor antagonist, BD-1047. Taken together, the findings of the current study suggest that YL-0919 activates the sigma-1 receptor, which mediates, at least to some extent, the rapid onset antidepressant effects of YL-0919. Thus, YL-0919 is a promising candidate as a fast-onset antidepressant that targets the sigma-1 receptor.

Keywords
Antidepressant; Fast-onset; Major depression; Molecular docking; YL-0919; σ-1 receptors.
Products
Inhibitors & Agonists
Other Products